Is PT-141 (Bremelanotide) Legal in California?

Print or save as PDF

Key numbers

  • 1.75 mgStrength of the prescription-only Vyleesi subcutaneous autoinjector for premenopausal womenSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 6 mmHgMaximal systolic blood pressure rise after one Vyleesi dose, per the labelSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 1.9 mmHgMean daytime systolic blood pressure rise in 127 premenopausal women dosed daily for 8 daysSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 8 doses per monthMonthly Vyleesi use limit: more than this number of doses per month is not recommendedSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026

See the public record for Bremelanotide

  • FDA status / Approved as Vyleesi (NDA 210557) on June 21, 2019 [1][2]
  • Form / 1.75 mg subcutaneous autoinjector, used as needed [1]
  • Prescription status / Prescription only [1]
  • Approved use / Premenopausal women with acquired, generalized HSDD [1]
  • Not approved for / Men, postmenopausal women, or enhancing sexual performance [1]
  • Boxed warning / None [1]

What the FDA approval covers

Vyleesi is bremelanotide, approved June 21, 2019 under NDA 210557 and now held by Cosette Pharmaceuticals [1][2]. It is a 1.75 mg subcutaneous autoinjector, prescription only [1].

The approved use is narrow: premenopausal women with acquired, generalized HSDD, meaning low sexual desire causing marked distress or interpersonal difficulty that is not due to a co-existing medical or psychiatric condition, relationship problems, or a medication or drug [1]. The label states it is not indicated for HSDD in postmenopausal women or in men, and not to enhance sexual performance [1].

PT-141 products that are not Vyleesi

Compounded and research-use products sold as PT-141 are not Vyleesi and are not FDA-approved drugs [3][1]. FDA does not review compounded drugs for safety, effectiveness or quality before they reach patients [4].

Bremelanotide does not appear on FDA's page of bulk substances that may present significant safety risks when compounded (content dated April 22, 2026), and it is not one of the six peptides in HHS's October 2026 draft enforcement-discretion policy [5][6][7]. Those facts do not make a compounded product FDA-approved.

Questions worth asking

Choose the questions you want to keep

What the label says about use and risk

The label contraindicates Vyleesi in patients with uncontrolled hypertension or known cardiovascular disease [1]. Each dose raises blood pressure briefly: the label reports maximal increases of 6 mmHg systolic and 3 mmHg diastolic, peaking 2 to 4 hours after the dose, with heart rate falling by up to 5 beats per minute and values usually back to baseline within 12 hours [1]. In an ambulatory study of 127 premenopausal women dosed daily for 8 days, mean daytime blood pressure rose 1.9 mmHg systolic and 1.7 mmHg diastolic [1].

The label reports that Vyleesi may slow gastric emptying and reduce absorption of oral medicines. It says to avoid Vyleesi with oral drugs that depend on threshold blood levels, such as antibiotics, and with oral naltrexone products intended to treat alcohol or opioid addiction [1].

Check what you know

Think you have it? Try 4 quick questions and see what the article says.

1. According to the article, are compounded PT-141 products FDA-approved drugs?

Question 1 of 4

Score: 0 right, 0 of 4 answered

Is PT-141 legal in California?
Bremelanotide is FDA-approved as Vyleesi and is prescription only [1][2]. FDA approval does not settle California-specific rules for prescribers, telehealth or pharmacies.
Do you need a prescription for PT-141?
Vyleesi is prescription only [1]. Compounded or research-use PT-141 products are not Vyleesi and are not FDA-approved drugs [3][1].
Is bremelanotide approved for men?
No. The label states Vyleesi is not indicated for HSDD in postmenopausal women or in men, and not to enhance sexual performance [1].
Does Vyleesi have a boxed warning or REMS?
No boxed warning appears in the label, and no REMS appears in the label or the 2019 approval letter [1][2].
How is Vyleesi used?
The label directs a 1.75 mg subcutaneous injection into the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity. It says not to use more than one dose in 24 hours, and that more than 8 doses per month is not recommended [1].

Reader questions

What people actually ask

Short answers drawn from the sources this article cites.

Where can I buy PT-141?

Vyleesi is the FDA-approved form and is prescription only. Compounded or research-use products sold as PT-141 are not Vyleesi and are not FDA-approved drugs, and FDA does not review them for safety, effectiveness or quality before they reach patients.

Can PT-141 be taken orally?

The approved form is a 1.75 mg subcutaneous autoinjector, not a pill. The label says Vyleesi may slow gastric emptying and reduce absorption of oral medicines, so it advises avoiding it with oral drugs that depend on threshold blood levels, such as antibiotics, and with oral naltrexone products used for alcohol or opioid addiction.

Is PT-141 safe to take?

The label contraindicates Vyleesi in patients with uncontrolled hypertension or known cardiovascular disease. Each dose raises blood pressure briefly, with maximal increases of 6 mmHg systolic and 3 mmHg diastolic peaking 2 to 4 hours after the dose, and values usually return to baseline within 12 hours.

Show all 7 referencesHide references
  1. U.S. National Library of Medicine, DailyMed. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector prescribing information. Vyleesi (bremelanotide) injection, 1.75 mg subcutaneous autoinjector label
  2. U.S. Food and Drug Administration. Approval letter, NDA 210557 (Vyleesi), 2019. FDA approval letter, NDA 210557
  3. Federal Register public inspection document 2026-22192, 2026.
  4. Human Drug Compounding Laws | FDA.
  5. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  6. U.S. Food and Drug Administration. FDA bulk drug substances lists. FDA bulk drug substances document
  7. U.S. Department of Health and Human Services. Peptide enforcement discretion policy, Appendix B, 2026. HHS peptide enforcement discretion policy, Appendix B
PT-141 legal California: evidence summary chart
Image: HealthRX.com. Full PT-141 legal California guide and sources at healthrx.com/peptide-legal-pt-141.